Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 272, Issue 1 35-1, 1997, Pages

  Yuen, V G ^a   Orvig, C ^a   Mcneill, J H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

diabetes; glucose lowering effect; streptozotocin

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; TRIACYLGLYCEROL; VANADIUM DERIVATIVE;

ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031030940     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1997.272.1.e30     Document Type: Article

References (39)

1. Battell, M. L., V. G. Yuen, and J. H. McNeill. Treatment of BB rats with vanadyl sulphate. Pharmacol. Commun. 1: 291-301, 1992.
2. Bhanot, S., M. Bryer-Ash, A. Cheung, and J. H. McNeill. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats. Diabetes 43: 857-861, 1994.
3. Bhanot, S., and J. H. McNcill. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension Dallas 24: 625-632, 1994.
4. Bhanot, S., J. H. McNeill, and M. Bryer-Ash. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension Dallas 23: 308-312, 1994.
5. Brichard, S. M., C. J. Bailey, and J. C. Henquin. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39: 1326-1332, 1990.
6. Brichard, S. M., B. Desbuquois, and J. Gerard. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: effects on glycolytic and gluconeogenic enzymes and on glucose transporter GLUT2. Mol. Cell. Endocrinol. 91: 91-97, 1993.
7. Brichard, S. M., J. Lederer, and J. C. Henquin. The insulin-like properties of vanadium a curiosity or a perspective for the treatment of diabetes? Diabete Metab. 17: 435-440, 1991
8. Brichard, S. M., W. Okitolonda, and J. C. Henquin. Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 123: 2048-2053, 1988.
9. Brichard, S. M., L. N. Ongemba, and J. C. Henquin. Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 35: 522-527, 1992.
10. Brichard, S. M., A. M. Pottier, and J. C. Henquin. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 125: 2510-2516, 1989.
11. Cam, M. C., J. Faun, and J. H. McNeill. Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats. Metab. Clin. Exp. 44: 332-339, 1995.
12. Cameron-Smith, D., G. R. Collier, and K. O'Dea. Reduction in hyperglycemia by mild food restriction in streptozotocin induced diabetic rats improves insulin sensitivity. Hormone Metab. Res. 26: 316-321, 1994.
13. Cohen, N., M. Halberstam, P. Shlimovich, C. J. Chang, H. Shamoon, and L. Rossetti. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with noninsulin-dependent diabetes mellitus. J. Clin. Invest. 95: 2501-2509, 1995.
14. Dai, S., K. H. Thompson, and J. H. McNeill. One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulphate. Pharmacol. Toxicol. 74: 101-109, 1994.
15. De Tata, V., M. Novelli, G. Cavallini, P. Masiello, Z. Gori, and E. Bergamini. Beneficial effects of oral administration of vanadyl sulphate on glucose metabolism in senescent rats. J. Gerontol. 48: B191-B195, 1993.
16. Dhalla, N. S., G. N. Pierce, I. R. Innes, and R. E. Beamish. Pathogenesis of cardiac dysfunction in diabetes mellitus. Can. J. Cardiol. 1: 263-281, 1985.
17. Factor, S. M., E. M. Okun, and R. Minase. Capillary microaneurysms in the human diabetic heart. N. Engl. J. Med. 302: 384-388, 1980.
18. Garcia, M. J., and P. M. McNamara. Morbidity and mortality in diabetics in the Framingham population. Diabetes 23: 105-111, 1974.
19. Goldfine, A. B., D. C. Simonson, F. Folli, M. E. Patti, and C. R. Kahn. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 80: 3311-3320, 1995.
20. Halberstam, M., N. Cohen, P. Shlimovich, L. Rossetti, and H. Shamoon. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45: 659-666, 1996.
21. Heyliger, C. E., A. G. Tahiliani, and J. H. McNeill. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science Wash. DC 227: 1474-1477, 1985.
22. +-dependent glucose transport in rat small intestine. Diabetes 42: 1126-1132, 1993.
23. Malabu, U. H., S. Dryden, H. D. McCarthy, A. Kilpatrick, and G. Williams. Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 43: 9-15, 1994.
24. McKibbin, P. E., H. D. McCarthy, P. Shaw, and G. Williams. Insulin deficiency is a specific stimulus to hypothalamic neuropeptide Y: a comparison of the effects of insulin replacement and food restriction in streptozocin-diabetic rats. Peptides 13: 721-727, 1992.
25. McNeill, J. H., and A. G. Tahiliani. Diabetes-induced cardiac changes. Trends Pharmacol. Sci. 7: 364-367, 1986.
26. McNeill, J. H., V. G. Yuen, H. R. Hoveyda, and C. Orvig. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. J. Med. Chem. 35: 1489-1491, 1992.
27. Rider, M. H., R. Bartons, and L. Hue. Vanadate inhibits liver fructose-2,6-bisphosphatase. Eur. J. Biochem. 190: 53-56, 1990.
28. Rossetti, L., A. Giaccari, E. Klein-Robbenhaar, and L. R. Vogel. Insulinomimetic properties of trace elements and characterization of their in vivo mode of action. Diabetes 39: 1243-1250, 1990.
29. Saxena, A. K., P. Srivastriva, and N. Z. Baquer. Effects of vanadate on glycolytic enzymes and malic enzyme in insulin-dependent and -independent tissues of diabetic rats. Eur. J. Pharmacol. 216: 123-126, 1992.
30. Sekar, N., A. Kanthasamy, S. William, S. Subramanian, and S. Govindasamy. Insulinic actions of vanadate in diabetic rats. Pharmacol. Res. 22: 207-217, 1990.
31. Scheen, A. J., N. Paquot, M. J. Catillo, and P. J. Lefebvre. How to measure insulin action in vivo. Diabetes Metab. 10: 151-188, 1994.
32. Shechter, Y., and S. J. D. Karlish. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl(IV) ions. Nature Lond. 284: 556-558, 1980.
33. Singer, D. E., W. Moulton, and D. M. Nathan. Diabetic MI: interaction of diabetes with other preinfarction risk factors. Diabetes 38: 350-357, 1989.
34. Takeuchi, K., K. Ueshima, T. Ohuchi, and S. Okabe. Induction of gastric lesions and hypoglycemic response by food deprivation in streptozotocin-diabetic rats. Dig. Dis. Sci. 39: 626-634, 1994.
35. Thompson, K. H., J. Leichter, and J. H. McNeill. Studies of vanadyl sulfate as a glucose-lowering agent in STZ-diabetic rats. Biochem. Biophys. Res. Commun. 197: 1549-1555, 1993.
36. Yuen, V. G., C. Orvig, and J. H. McNeill. Glucose-lowering effect of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol. 71: 263-269, 1993.
37. Yuen, V. G., C. Orvig, K. H. Thompson, and J. H. McNeill. Improvement in cardiac dysfunction in STZ-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol. 71: 270-276, 1993.
38. Yuen, V. G., C. Orvig, and J. H. McNeill. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can. J. Physiol. Pharmacol. 73: 55-64, 1994.
39. Yuen, V. G., R. A. Pederson, C. Orvig, and J. H. McNeill. The effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can. J. Physiol. Pharmacol. In press.